Combination Nivolumab and Ipilimumab Shows Efficacy in Advanced Melanoma
Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the design and efficacy of the phase III CheckMate 067 trial for patients with advanced melanoma.<br />
Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses the design and efficacy of the phase III CheckMate 067 trial for patients with advanced melanoma.
This was a 3-arm randomized trial which investigated ipilimumab (Yervoy), an anti-CTLA4 therapy, and nivolumab (Opdivo), an anti-PD-1 therapy, in combination versus ipilimumab alone versus nivolumab alone. Long says the combination of nivolumab and ipilimumab was not originally powered to be compared to the nivolumab monotherapy, but descriptive analyses have been completed. These data looked at the 5-year overall survival (OS) for patients with advanced melanoma on these regimens.
The descriptive analysis showed that the landmark OS at 5 years was high, according to Long. She explains that survival remained the highest with the combination of nivolumab and ipilimumab at about 52%, whereas with nivolumab alone, it was about 44% and with ipilimumab, it was the lowest, at about 26%.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
